BRPI0810123A2 - Derivados de ftalazina e isoquinolina com atividades moduladoras do receptor de s1p - Google Patents
Derivados de ftalazina e isoquinolina com atividades moduladoras do receptor de s1pInfo
- Publication number
- BRPI0810123A2 BRPI0810123A2 BRPI0810123-0A2A BRPI0810123A BRPI0810123A2 BR PI0810123 A2 BRPI0810123 A2 BR PI0810123A2 BR PI0810123 A BRPI0810123 A BR PI0810123A BR PI0810123 A2 BRPI0810123 A2 BR PI0810123A2
- Authority
- BR
- Brazil
- Prior art keywords
- ftaazine
- isoquinoline derivatives
- modulating activities
- receiver modulating
- receiver
- Prior art date
Links
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical class C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07106753 | 2007-04-23 | ||
| PCT/EP2008/054797 WO2008129029A1 (en) | 2007-04-23 | 2008-04-21 | Phthalazine and isoquinoline derivatives with slp receptor modulating activities |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0810123A2 true BRPI0810123A2 (pt) | 2014-10-29 |
Family
ID=38582125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0810123-0A2A BRPI0810123A2 (pt) | 2007-04-23 | 2008-04-21 | Derivados de ftalazina e isoquinolina com atividades moduladoras do receptor de s1p |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20100179153A1 (pt) |
| EP (1) | EP2148863A1 (pt) |
| JP (1) | JP2010525016A (pt) |
| KR (1) | KR20100015857A (pt) |
| CN (1) | CN101679274A (pt) |
| AU (1) | AU2008240679A1 (pt) |
| BR (1) | BRPI0810123A2 (pt) |
| CA (1) | CA2684965A1 (pt) |
| EA (1) | EA200901389A1 (pt) |
| MX (1) | MX2009011421A (pt) |
| WO (1) | WO2008129029A1 (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2548353T3 (es) * | 2006-12-28 | 2015-10-15 | Abbvie Inc. | Inhibidores de poli(ADP-ribosa)polimerasa |
| US8466150B2 (en) | 2006-12-28 | 2013-06-18 | Abbott Laboratories | Inhibitors of poly(ADP-ribose)polymerase |
| TWI522361B (zh) | 2010-07-09 | 2016-02-21 | 艾伯維公司 | 作為s1p調節劑的稠合雜環衍生物 |
| TW201206893A (en) * | 2010-07-09 | 2012-02-16 | Abbott Healthcare Products Bv | Bisaryl (thio) morpholine derivatives as S1P modulators |
| TW201643169A (zh) | 2010-07-09 | 2016-12-16 | 艾伯維股份有限公司 | 作為s1p調節劑的螺-哌啶衍生物 |
| WO2012164103A2 (en) | 2011-06-03 | 2012-12-06 | Universität Zürich | Blockers of the nogo-a s1pr pathway for the treatment of diseases characterized by neuronal damage and lack of subsequent repair |
| WO2018155260A1 (ja) * | 2017-02-23 | 2018-08-30 | 株式会社Ihi | Ｏｈラジカル検出プローブ、ｏｈラジカル測定装置、および、ｏｈラジカル測定方法 |
| US11535632B2 (en) | 2019-10-31 | 2022-12-27 | ESCAPE Bio, Inc. | Solid forms of an S1P-receptor modulator |
| EP4291235A4 (en) * | 2021-02-12 | 2025-01-08 | Nimbus Saturn, Inc. | HPK1 ANTAGONISTS AND USES THEREOF |
| WO2022213062A1 (en) | 2021-03-29 | 2022-10-06 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
| CN118234492A (zh) * | 2022-10-21 | 2024-06-21 | 次代生物科学株式会社 | 具有针对s1pr1和s1pr4的功能性抑制剂作用的用于预防或治疗圆形脱发症的药物组合物 |
| KR102541577B1 (ko) * | 2022-10-21 | 2023-06-13 | 주식회사 넥스트젠바이오사이언스 | S1pr1과 s1pr4에 대한 기능적 저해제로 작용하는 원형 탈모증의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2063249A (en) * | 1979-10-09 | 1981-06-03 | Mitsubishi Yuka Pharma | 4-Phenylphthalazine derivatives |
| PT1254138E (pt) * | 2000-02-09 | 2005-09-30 | Novartis Ag | Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf |
| RU2167659C1 (ru) * | 2000-08-02 | 2001-05-27 | Закрытое акционерное общество "Центр современной медицины "Медикор" | Способ коррекции иммунной системы живого организма |
| KR20110140139A (ko) * | 2003-08-29 | 2011-12-30 | 오노 야꾸힝 고교 가부시키가이샤 | Ｓ１ｐ 수용체 결합능을 갖는 화합물 및 그 의약 용도 |
| CN1905873A (zh) * | 2003-11-19 | 2007-01-31 | 阵列生物制药公司 | Mek的杂环抑制剂及其使用方法 |
| TW201016688A (en) * | 2008-10-20 | 2010-05-01 | Lundbeck & Co As H | Isoquinolinone derivatives as NK3 antagonists |
-
2008
- 2008-04-21 WO PCT/EP2008/054797 patent/WO2008129029A1/en not_active Ceased
- 2008-04-21 CA CA002684965A patent/CA2684965A1/en not_active Abandoned
- 2008-04-21 EP EP08749628A patent/EP2148863A1/en not_active Withdrawn
- 2008-04-21 KR KR1020097022224A patent/KR20100015857A/ko not_active Withdrawn
- 2008-04-21 EA EA200901389A patent/EA200901389A1/ru unknown
- 2008-04-21 US US12/597,100 patent/US20100179153A1/en not_active Abandoned
- 2008-04-21 MX MX2009011421A patent/MX2009011421A/es not_active Application Discontinuation
- 2008-04-21 CN CN200880014650A patent/CN101679274A/zh active Pending
- 2008-04-21 JP JP2010504651A patent/JP2010525016A/ja active Pending
- 2008-04-21 BR BRPI0810123-0A2A patent/BRPI0810123A2/pt not_active Application Discontinuation
- 2008-04-21 AU AU2008240679A patent/AU2008240679A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008129029A1 (en) | 2008-10-30 |
| EP2148863A1 (en) | 2010-02-03 |
| MX2009011421A (es) | 2009-12-15 |
| JP2010525016A (ja) | 2010-07-22 |
| AU2008240679A1 (en) | 2008-10-30 |
| CA2684965A1 (en) | 2008-10-30 |
| KR20100015857A (ko) | 2010-02-12 |
| CN101679274A (zh) | 2010-03-24 |
| US20100179153A1 (en) | 2010-07-15 |
| EA200901389A1 (ru) | 2010-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0810123A2 (pt) | Derivados de ftalazina e isoquinolina com atividades moduladoras do receptor de s1p | |
| FIC20220033I1 (fi) | Finerenoni sekä sen suolat, solvaatit ja suolojen solvaatit | |
| BRPI0920962A2 (pt) | variantes de polipeptídeos receptores de activina iib e usos dos mesmos | |
| BRPI0812004A2 (pt) | Dispositivo de travamento e nacela de turbojato | |
| BRPI0918046A2 (pt) | gerenciamento de autenticação de usuário | |
| CR10930A (es) | Moduladores receptores nicotinicos de acetilcolina | |
| ES2355534T8 (es) | Derivados de isoquinolina e isoquinolinona sustituidos con cicloalquilamina. | |
| EP3270564C0 (en) | Distributed security provisioning | |
| BRPI0815092A2 (pt) | Moduladores duais de receptores 5-ht2a e d3 | |
| FI20070177L (fi) | Turvajärjestely | |
| BRPI0917394A2 (pt) | moduladores de mif | |
| BRPI0812436A2 (pt) | Modulação de receptores quimiossensores e ligantes associados com eles | |
| FI20075532A0 (fi) | Uusia esteraaseja ja niiden käyttö | |
| BRPI0815661A2 (pt) | Dispositivo de distribuição com travamento | |
| EP2162132A4 (en) | Heterocyclic kinase modulators | |
| PL2498610T5 (pl) | Selektywne modulatory receptora sfingozyno-1-fosforanu i sposoby syntezy chiralnej | |
| BRPI0817245A2 (pt) | Derivados e quinolina como antagonistas receptores de 5ht5a | |
| BRPI0812247A2 (pt) | Derivados de piridazinona | |
| FI20075892L (fi) | Kommunikointi- ja kulunseurantajärjestely | |
| EP2333393A4 (en) | Joint unit | |
| DK2297100T3 (da) | Tetrahydrocyclopenta[b]indol-androgenreceptor-modulatorer | |
| DE602009000150D1 (de) | Kommunikationssystem und Kommunikationsvorrichtung | |
| EP2464051A4 (en) | SYSTEM FOR ORDER OF FUNCTIONAL ENCRYPTIONS | |
| BRPI0923497A2 (pt) | derivados de piridazinona | |
| BRPI0922597A8 (pt) | ftalazinona e análogos relacionados como moduladores de sirtuína |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |